Christopher C.W. Hughes

This study investigates how SARS-CoV-2 RNA and nucleocapsid-containing immune complexes drive inflammation and endothelial dysfunction through Fcγ receptor and TLR-8 pathways.

This paper develops a microphysiological HHT-on-a-chip platform that recapitulates patient vascular lesions and demonstrates sensitivity to pazopanib, a drug effective in HHT patients.

The paper introduces the ImmuniT platform, which improves neoantigen prediction in lung cancer by identifying more immunogenic targets than conventional methods.

This study identifies PHLDA2 as a driver of breast cancer metastasis by reactivating a placental vascular remodeling program through hypomethylation and SPARC-mediated effects.

This study identifies CDC42 inhibitors that reduce vessel branching in both normal skin and tumors, offering potential for treating skin cancer and angiogenesis-related diseases.

This paper designs a CDC42 effector interaction inhibitor (ARN22089) that shows anti-cancer activity by blocking tumor invasion and angiogenesis.